Sample Analysis Sample Clauses

Sample Analysis. In respect of Category A Regulated Materials: Customer agrees that the analysis of the sampling must: (i) be performed by a laboratory acceptable to Lessor that is certified to perform such analysis by the country in which the Equipment is located; (ii) be documented to United’s satisfaction, and must include a record of the chain of custody for the Representative Samples;

Sample Analysis. List and discuss all analyses proposed for the project. Include a table that summarizes the following information for each analysis to be performed: o Analytical Parameters o Analytical Method Reference Number (from USEPA SW 846) o Sample Preparation and/or Extraction Method Reference Number (from USEPA SW 846) o Detection and Practical Quantitation Limits (Data above the detection limit but below the practical quantitation limit must be reported with the estimated concentration.) Discuss the rationale for selection of the analytical parameters. The rationale must relate to site history and the RFI objectives. The achievable detection limits or quantitation limits stated in the selected methods must be adequate for valid comparisons of analytical results against any action levels or standards. For example, the objective may be to collect ground water data for comparison with Maximum Contaminant Levels (MCL's). If this were the case, it would be important to ensure that any ground water test methods had detection limits below the MCL's. Give an explanation if all samples from the same medium will not be analyzed for the same parameters. Provide the name(s) of the laboratory(s) that will be doing the analytical work. Indicate any special certifications or ratings of the laboratory. Describe the steps that will be taken to select and pre-qualify analytical laboratories to be used including any previous audits and/or other criteria. If a definite laboratory has not yet been selected, list at least 3 laboratories that are being considered for the analytical work.

Sample Analysis. List and discuss all analysis proposed for the project. Include a table that summarizes the following information for each analysis to be performed: *Analytical Parameters *Analytical Method Reference Number (from EPA SW 846) *Sample Preparation and/or Extraction Method Reference Number (from SW 846) *Detection and Practical Quantitation Limits (Data above the detection limit but below the practical quantitation limit must be reported with the estimated concentration.) Discuss the rationale for selection of the analytical parameters. The rationale must relate to site history and the RFI objectives. The achievable detection limits or quantitation limits stated in the selected methods must be adequate for valid comparisons of analytical results against any action levels or standards. Give an explanation if all samples from the same matrix will not be analyzed for the same parameters. Provide the name(s) of the laboratory(s) that will be doing the analytical work. Indicate any special certifications or ratings of the laboratory. Describe the steps that will be taken to select and pre-qualify analytical laboratories to be used including any previous audits and/or other criteria. If a define laboratory has not yet been selected, list at least 3 laboratories that are being considered for the analytical work.

Sample Analysis. 1 The minimum drug screening sensitivity limits are as follows: Marijuana Metabolite 50 15 Cocaine Metabolite 300 150 Opiates: 2000 300 Morphine 2000 Codeine 2000 6-Acetylmorphine 10 Hydrocodone 300 Hydromorphone 300 Oxycodone 300 Phencyclidine 25 25 Amphetamine: 1000 Amphetamine 500 Methamphetamine 500 Barbiturates: 300 Amobarbital 300 Butalbital 300 Pentobarbital 300 Phenobarbital 300 Secobarbital 300 Benzodiazepines: 300 Alprazolam Metabolite 300 Triazolam Metabolite 300 Flurazepam Metabolite 300 Lorazepam 300 Nordiazepam 300 Oxazepam 300 Temazepam 300 Methadone: 300 Methadone 300 Norpropoxyphene 300 300 Alcohol 0.02 gm/dL 0.02 gm/dL 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Sample Analysis. Licensor shall have the right to analyze samples of the Licensee Product at any time and from time to time for purposes of verifying that Licensee has complied with any conditions that may be applicable to the pricing alternative(s) selected by Licensee for any order of the Martek Products. The expenses of such analyses shall be borne by Licensor; provided, however, that Licensee shall provide reasonable samples to Licensor without charge upon Licensor’s request, to be made no more often than quarterly, and provided, further, that Licensee shall be charged for, and shall promptly pay the expense of any such analysis that discloses a failure to comply with any applicable condition.

Sample Analysis. The Food Safety Laboratory Service shall provide services for microbiological, chemical and other testing of foodstuffs for parameters including contaminants. Analysis shall be carried out in accordance with the Section 3 taking into account the relevant legislative requirements, guidelines and/or protocols. It is recognised that sampling and analysis may be required outside the agreed national/regional sampling programmes. In this regard the Authority and the Environmental Health Service will firstly request the assistance of the Food Safety Laboratory Service. In the event of a food-poisoning outbreak (or other food contamination incident) the routine testing programme may have to be adjusted to deal with this. The sampling and testing regime will be flexible, to allow for emergency analysis as required.

Sample Analysis. Kite shall provide to Humanigen the Samples necessary for Humanigen to perform the Sample Analysis for which Humanigen is responsible, pursuant to the Sample Analysis Plan. Each Party, at its own expense, shall perform (directly or through an Affiliate or Third Party acting on its behalf) the testing procedures and analyses of the Samples (together “Sample Analysis/es”) pursuant to the sample analysis plan attached hereto as Exhibit C (“Sample Analysis Plan”), which shall be set forth in the Protocol. The Sample Analyses shall be performed by a Party in accordance with the timeline set forth in the Sample Analysis Plan or otherwise determined by the JDC.

Sample Analysis. (a) Upon Biosite’s written request, Power3 shall provide to Biosite, prior to one (1) month following the first delivery of Program Antibodies, non-degraded, intact, properly shipped, blood-based clinical samples (each sample being approximately 2ml, but not less than 1.5ml, in volume) previously obtained by Power3 from its clinical trials being conducted at New York University, Mercy Hospital and OGA (the “Samples”). With respect to each Sample, Power3 shall (i) provide Biosite with such information, that is not subject to confidentiality obligations pursuant to the Health Insurance Portability and Accountability Act (“HIPPA”) and the clinical trial and material transfer agreements under which the Samples and clinical data were collected, regarding such Sample as Power3 has in its possession and control; (ii) have obtained the requisite patient consent forms to permit the use contemplated hereunder of all such Samples and associated clinical data, together with all progeny, products and information derived therefrom, for research and development without compensation to the donor; (iii) prepare and maintain complete and accurate records of Sample sources, donor medical history, Sample procurement and any infectious disease screening, together with any other records regarding the Samples required by applicable laws and regulations; (iv) provide Biosite with copies of all such patient consent forms and records upon request, provided that Power3 shall redact patient names and other patient identifying information for confidentiality purposes; and (v) advise Biosite of any Third Party restrictions applicable to the use of such Samples at the time of, or prior to, providing such Samples to Biosite. (b) Biosite shall treat all Samples and clinical data as Confidential Information and shall not publish, sell, lease, or otherwise transfer or disclose such Samples and clinical data to any other party without the express consent of Power3; provided, however, that Biosite shall have the right to publish and include in its marketing brochures summaries of the clinical data. Notwithstanding the foregoing, Biosite shall have the right to use all Samples and associated clinical data, together with all progeny, products and information derived therefrom, for research and development purposes, as long as Biosite use complies with HIPPA, Third Party restrictions provided to Biosite under Section 3.1.5(a) above, and any other current or future government regulations governin...

Sample Analysis. The maternal serum concentrations of FT3, FT4, TSH, anti-TPO and anti-Tg were measured by immunoassay using direct, chemiluminometric technology (Siemens Advia Centaur assays, Siemens Healthcare Diagnostics Ltd, Surrey, UK).